At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
irinotecan hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Irinotecan + Temozolomide in Children With Recurrent Neuroblastoma
In Brief
A Phase 2 clinical trial evaluating irinotecan hydrochloride and temozolomide for Neuroblastoma. Completed, enrolled 59 participants across 128 sites in 3 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with temozolomide works in treating young patients with recurrent neuroblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesAustralia, Canada, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionMar 2009
Study CompletionDec 2013
TodayJul 2026
First PostedApr 6, 2006
Enrollment StartApr 1, 2006
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.2 years ago
Interventions
irinotecan hydrochloridedrug
Given IV
temozolomidedrug
Given IV